Subscribe to RSS
DOI: 10.1055/s-2007-963693
© Georg Thieme Verlag KG Stuttgart · New York
Die Kombination von Pharmakologie und Vitrektomie kann die Grenzen der mechanischen vitreoretinalen Chirurgie überwinden
The Need for Pharmacology in Vitreoretinal SurgerySOE Lecture 2007Publication History
Eingegangen: 15.10.2007
Angenommen: 22.10.2007
Publication Date:
18 December 2007 (online)

Zusammenfassung
Hintergrund: Trotz aller technischer Entwicklungen, welche die Vitrektomie in den 35 Jahren seit ihrer Erfindung zu einem hoch effektiven und sicheren Routineverfahren der intraokularen Chirurgie werden ließen, stößt die mechanische Glaskörperentfernung und Manipulation der Netzhaut an ihre Grenzen. Material und Methoden: Durch die Zusammenschau klinischer und pathologischer, meist ultrastruktureller Befunde werden die Grenzen der Vitrektomie aufgezeigt und Lösungsansätze aktueller und zukünftiger Forschungsaktivitäten vorgestellt. Ergebnisse: Die Grenzen der Vitrektomie sind: 1. Inkomplette Glaskörperentfernung. 2. Therapie von Spätstadien. 3. Fehlende Neuroprotektion. 4. Ungenügend sicher definierte Dissektionsebenen. Diese Grenzen lassen sich nur in Kombination der Chirurgie mit der Pharmakologie überwinden. Schlussfolgerungen: Folgende Forschungs- und Lösungsansätze werden vorgestellt: Ad 1. Pharmakologische Vitreolyse. Ad 2. Frühere, weniger traumatische Intervention. Ad 3. Neuroprotektion und antiproliferative Substanzen. Ad 4. Selektive Anfärbung von Glaskörperrinde und ILM.
Abstract
Background: While the limits of mechanical vitrectomy are being approached, scientists and vitreoretinal surgeons are looking for a combination of pharmacology and vitrectomy, i. e., pharmacology-assisted vitrectomy. Methods: This review shows the limits of conventional vitreoretinal surgery by presenting clinical and ultrastructural data related to vitreoretinal surgical techniques and outcomes. Results: The limits of conventional vitreoretinal surgery include: 1. Incomplete vitreous cortex removal. 2. Surgery of advanced stages of the disease. 3. The lack of neuroprotection and antiproliferative agents. 4. Ill-defined cleavage planes when removing tissue from the retina. Conclusions: Pharmacology-assisted vitrectomy helps to overcome the limits of conventional vitreoretinal surgery by addressing: Item 1. Pharmacological vitreolysis. Item 2. Earlier, less traumatic intervention. Item 3. Neuroprotection and antiproliferative agents. Item 4. Selective staining of distinct structures of the vitreoretinal interface, such as cortical vitreous, cellular proliferation, and internal limiting membrane.
Schlüsselwörter
Glaskörper - Pathologie - Retina
Key words
pathology - retina - vitreous
Literatur
- 1 Ansari R R, Suh K I, Sebag J. Dynamic light scattering (DLS) quantifies the effects of microplasmin pharmacologic
vitreolysis. Poster at the 5th International Symposium on Ocular Pharmacology and
Therapeutics (ISOPT). Monte Carlo; 2004
MissingFormLabel
- 2
Bonnet M.
The development of severe proliferative vitreoretinopathy after retinal detachment
surgery. Grade B: a determining risk factor.
Graefes Arch Clin Exp Ophthalmol.
1988;
226 (3)
201-205
MissingFormLabel
- 3
Capeans C, Lorenzo J, Santos L. et al .
Comparative study of incomplete posterior vitreous detachment as a risk factor for
proliferative vitreoretinopathy.
Graefes Arch Clin Exp Ophthalmol.
1998;
236 (7)
481-485
MissingFormLabel
- 4
Charteris D G, Sethi C S, Lewis G P. et al .
Proliferative vitreoretinopathy: developments in adjunctive treatment and retinal
pathology.
Eye.
2002;
16
369-374
MissingFormLabel
- 5
Eibl K H, Lewis G P, Betts K. et al .
The effect of alkylphosphocholines on intraretinal proliferation initiated by experimental
retinal detachment.
Invest Ophthalmol Vis Sci.
2007;
48 (3)
1305-1311
MissingFormLabel
- 6
Faulborn J, Bowald S.
Microproliferations in proliferative diabetic retinopathy and their relationship to
the vitreous: corresponding light and electron microscopic studies.
Graefes Arch Clin Exp Ophthalmol.
1985;
223 (3)
130-138
MissingFormLabel
- 7
Foos R Y.
Vitreoretinal juncture; topographical variations.
Invest Ophthalmol Vis Sci.
1972;
11 (10)
801-808
MissingFormLabel
- 8
Gandorfer A.
Pharmacologic vitreolysis.
Dev Ophthalmol.
2007;
39
149-56
MissingFormLabel
- 9
Gandorfer A, Messmer E M, Ulbig M W. et al .
Resolution of diabetic macular edema after surgical removal of the posterior hyaloid
and the inner limiting membrane.
Retina.
2000;
20 (2)
126-133
MissingFormLabel
- 10
Gandorfer A, Priglinger S, Schebitz K. et al .
Vitreoretinal morphology of plasmin-treated human eyes.
Am J Ophthalmol.
2002;
133 (1)
156-159
MissingFormLabel
- 11
Gandorfer A, Putz E, Welge-Lussen U. et al .
Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy.
Br J Ophthalmol.
2001;
85 (1)
6-10
MissingFormLabel
- 12
Gandorfer A, Rohleder M, Charteris D. et al .
Ultrastructure of vitreomacular traction syndrome associated with persistent hyaloid
artery.
Eye.
2005;
19 (3)
333-336
MissingFormLabel
- 13
Gandorfer A, Rohleder M, Charteris D G. et al .
Staining and peeling of the internal limiting membrane in the cat eye.
Curr Eye Res.
2005;
30 (11)
977-987
MissingFormLabel
- 14
Gandorfer A, Rohleder M, Grosselfinger S. et al .
Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular
traction.
Am J Ophthalmol.
2005;
139 (4)
638-652
MissingFormLabel
- 15
Gandorfer A, Rohleder M, Kampik A.
Epiretinal pathology of vitreomacular traction syndrome.
Br J Ophthalmol.
2002;
86 (8)
902-909
MissingFormLabel
- 16
Gandorfer A, Rohleder M, Sethi C. et al .
Posterior vitreous detachment induced by microplasmin.
Invest Ophthalmol Vis Sci.
2004;
45 (2)
641-647
MissingFormLabel
- 17
Gandorfer A, Ulbig M, Kampik A.
Plasmin-assisted vitrectomy eliminates cortical vitreous remnants.
Eye.
2002;
16 (1)
95-97
MissingFormLabel
- 18
Gauthier R, Joly S, Pernet V. et al .
Brain-derived neurotrophic factor gene delivery to muller glia preserves structure
and function of light-damaged photoreceptors.
Invest Ophthalmol Vis Sci.
2005;
46 (9)
3383-3392
MissingFormLabel
- 19
Hageman G S, Russell S R.
Chondroitinase-mediated disinsertion of the primate vitreous body.
Invest Ophthalmol Vis Sci.
1994;
35
1260
MissingFormLabel
- 20
Haritoglou C, Gass C A, Kristin N. et al .
Paracentral scotomata: a new finding after vitrectomy for idiopathic macular hole.
British Journal of Ophthalmology.
2001;
85
231-233
MissingFormLabel
- 21
Haritoglou C, Reiniger I W, Schaumberger M. et al .
Five-year follow-up of macular hole surgery with peeling of the internal limiting
membrane: update of a prospective study.
Retina.
2006;
26 (6)
618-622
MissingFormLabel
- 22
Haritoglou C, Schumann R, Reiniger I. et al .
Evaluation of the internal limiting membrane after conventional peeling during macular
hole surgery.
Retina.
2006;
26 (1)
21-24
MissingFormLabel
- 23
Haritoglou C, Tadayoni R, May C A. et al .
Short-term in vivo evaluation of novel vital dyes for intraocular surgery.
Retina.
2006;
26 (6)
673-678
MissingFormLabel
- 24
Kampik A, Green W R, Michels R G. et al .
Ultrastructural features of progressive idiopathic epiretinal membrane removed by
vitreous surgery.
Am J Ophthalmol.
1980;
90 (6)
797-809
MissingFormLabel
- 25
Kampik A, Kenyon K R, Michels R G. et al .
Epiretinal and vitreous membranes. Comparative study of 56 cases.
Arch Ophthalmol.
1981;
99 (8)
1445-1454
MissingFormLabel
- 26
Kohno T, Sorgente N, Ishibashi T. et al .
Immunofluorescent studies of fibronectin and laminin in the human eye.
Invest Ophthalmol Vis Sci.
1987;
28 (3)
506-514
MissingFormLabel
- 27
Kuppermann B D, Thomas E L, Smet M D. et al .
Pooled efficacy results from two multinational randomized controlled clinical trials
of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase)
for the management of vitreous hemorrhage.
Am J Ophthalmol.
2005;
140 (4)
573-584
MissingFormLabel
- 28
Kuppermann B D, Thomas E L, Smet de M D. et al .
Safety results of two phase III trials of an intravitreous injection of highly purified
ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.
Am J Ophthalmol.
2005;
140 (4)
585-597
MissingFormLabel
- 29
Lewis G P, Charteris D G, Sethi C S. et al .
The ability of rapid retinal reattachment to stop or reverse the cellular and molecular
events initiated by detachment.
Invest Ophthalmol Vis Sci.
2002;
43 (7)
2412-2420
MissingFormLabel
- 30
Lewis G P, Guerin C J, Anderson D H. et al .
Rapid changes in the expression of glial cell proteins caused by experimental retinal
detachment.
Am J Ophthalmol.
1994;
118 (3)
368-376
MissingFormLabel
- 31
Lewis G P, Linberg K A, Geller S F. et al .
Effects of the neurotrophin brain-derived neurotrophic factor in an experimental model
of retinal detachment.
Invest Ophthalmol Vis Sci.
1999;
40 (7)
1530-1544
MissingFormLabel
- 32
Lewis G P, Sethi C S, Linberg K A. et al .
Experimental retinal reattachment: a new perspective.
Mol Neurobiol.
2003;
28 (2)
159-175
MissingFormLabel
- 33
Machemer de R, Norton E W.
A new concept for vitreous surgery. Indications and results.
Am J Ophthalmol.
1972;
74 (6)
1034-1056
MissingFormLabel
- 34
Machemer R, Norton E W.
Vitrectomy, a pars plana approach. II Clinical experience.
Mod Probl Ophthalmol.
1972;
10
178-185
MissingFormLabel
- 35
Machemer R, Parel J M, Norton E W.
Vitrectomy: a pars plana approach. Technical improvements and further results.
Trans Am Acad Ophthalmol Otolaryngol.
1972;
76 (2)
462-466
MissingFormLabel
- 36
Margherio A R, Margherio R R, Hartzer M. et al .
Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes.
Ophthalmology.
1998;
105 (9)
1617-1620
MissingFormLabel
- 37
Schumann R G, Schaumberger M M, Rohleder M. et al .
Ultrastructure of the vitreomacular interface in full-thickness idiopathic macular
holes: a consecutive analysis of 100 cases.
Am J Ophthalmol.
2006;
141 (6)
1112-1119
MissingFormLabel
- 38
Schwartz S D, Alexander R, Hiscott P. et al .
Recognition of vitreoschisis in proliferative diabetic retinopathy. A useful landmark
in vitrectomy for diabetic traction retinal detachment.
Ophthalmology.
1996;
103 (2)
323-328
MissingFormLabel
- 39
Stefansson E, Landers III M B, Wolbarsht M L.
Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy
and lensectomy.
Trans Am Ophthalmol Soc.
1981;
79
307-334
MissingFormLabel
- 40
Stefansson E, Landers III M B, Wolbarsht M L.
Vitrectomy, lensectomy, and ocular oxygenation.
Retina.
1982;
2 (3)
159-166
MissingFormLabel
- 41
Tezel T H, Del Priore L V, Kaplan H J.
Posterior vitreous detachment with dispase.
Retina.
1998;
18 (1)
7-15
MissingFormLabel
- 42
Trese M.
Enzymatic-assisted vitrectomy.
Eye.
2002;
16
365-368
MissingFormLabel
- 43
Verma L, Prakash G, Tewari H K.
Diabetic retinopathy: time for action.
No complacency please! Bull World Health Organ.
2002;
80 (5)
419
MissingFormLabel
- 44
Verstraeten T C, Chapman C, Hartzer M. et al .
Pharmacologic induction of posterior vitreous detachment in the rabbit.
Arch Ophthalmol.
1993;
111 (6)
849-854
MissingFormLabel
- 45
Williams J G, Trese M T, Williams G A. et al .
Autologous plasmin enzyme in the surgical management of diabetic retinopathy.
Ophthalmology.
2001;
108 (10)
1902-1905
MissingFormLabel
Priv.-Doz. Dr. A. Gandorfer
Vitreoretinal and Pathology Unit, Universitäts-Augenklinik München
Mathildenstr. 8
80336 München
Phone: ++ 49/89/51 60 38 56
Fax: ++ 49/89/51 60 47 78
Email: arnd.gandorfer@med.uni-muenchen.de